Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ: PEPG )

5.120 -0.380 (-6.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 95,855
Open 5.500
Bid (Size) 2.190 (1)
Ask (Size) 8.440 (2)
Prev. Close 5.500
Today's Range 5.090 - 5.550
52wk Range 4.710 - 20.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1) 
From PepGen Inc.
Via GlobeNewswire
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
From PepGen Inc.
Via GlobeNewswire

Performance

YTD
-61.59%
-61.59%
1 Month
-6.06%
-6.06%
3 Month
-46.33%
-46.33%
6 Month
-59.91%
-59.91%
1 Year
+1.39%
+1.39%

More News

Read More
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
From PepGen Inc.
Via GlobeNewswire
The Latest Analyst Ratings for PepGen
Via Benzinga
PepGen: Q1 Earnings Insights
Via Benzinga
Why This PepGen Analyst Is Bullish On The Biotech Stock
Via Benzinga
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
SAIC, HealthEquity And 3 Stocks To Watch Heading Into Monday
Via Benzinga
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
Via Benzinga
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Earnings Scheduled For March 23, 2023
Via Benzinga
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
From PepGen Inc.
Via GlobeNewswire
PepGen to Participate in the SVB Securities Global Biopharma Conference
From PepGen Inc.
Via GlobeNewswire
Around $12M Bet On This Technology Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
From PepGen Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.